Urologic Neoplasms: Clinical Trials

4,373 trials for Urologic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1932 completed, 689 recruiting, 521 unknown, 518 terminated. 1543 Phase 2, 1088 Phase 1, 738 Not applicable, 349 Phase 3, 74 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21543Completed 668, Terminated 263, Recruiting 211, Unknown 140, Active not recruiting 138, Not yet recruiting 59, Withdrawn 58, Suspended 4, Enrolling by invitation 2
Phase 11088Completed 515, Terminated 171, Recruiting 156, Active not recruiting 104, Unknown 72, Withdrawn 37, Not yet recruiting 25, Suspended 7, Enrolling by invitation 1
Not applicable738Completed 283, Recruiting 147, Unknown 128, Terminated 54, Not yet recruiting 45, Withdrawn 36, Active not recruiting 34, Enrolling by invitation 8, Suspended 3
Phase 3349Completed 149, Recruiting 52, Active not recruiting 48, Terminated 36, Unknown 35, Withdrawn 15, Not yet recruiting 13, Enrolling by invitation 1
Phase 474Completed 34, Unknown 16, Recruiting 11, Terminated 8, Not yet recruiting 3, Withdrawn 2
Early Phase 161Completed 31, Recruiting 7, Terminated 7, Active not recruiting 6, Unknown 4, Withdrawn 3, Not yet recruiting 2, Suspended 1

Follow Urologic Neoplasms: new trials by email Literature Review of Urologic Neoplasms trials Research Report on Urologic Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of Naloxegol in the Prevention of POI After Cystectomy
Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications
Phase 2WithdrawnInstitut Paoli-Calmettes2032-01-012026-10-14
Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer
AI Uro-Cam - Bladder Cancer
Not applicableNot yet recruitingChinese University of Hong Kong602028-07-012026-10-28
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8
Phase 2RecruitingNational Cancer Institute (NCI)162027-05-172026-10-21
Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer
Cyclophosphamide, Fludarabine, Aldesleukin (IL-2) - Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer)
Phase 2Not yet recruitingBeth Israel Deaconess Medical Center102027-04-262026-11-09
Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)
This is a non-interventional, observational, prospective study. - NMIBC, MIBC
Not yet recruitingBladder Cancer Advocacy Network14002027-03-012026-10-26
Hugo™ RAS Urology Post-Market Clinical Study
Robotic Assisted Urologic Surgery - Prostatectomy, Cystectomy
Not yet recruitingMedtronic - MITG1102027-02-232026-10-30
Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma
Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Phase 3Not yet recruitingNational Cancer Institute (NCI)4002027-02-102026-07-08
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma
Phase 2Not yet recruitingFujian Cancer Hospital272027-02-012026-10-01
A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer
NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
Phase 3Not yet recruitingRelmada Therapeutics, Inc.3932027-02-012026-09-02
DK222 Study at Hopkins
[18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer
Phase 1RecruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins62027-01-312026-09-29
Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma
BCG Solution, Best Practice, Cystoscopy - Non-Muscle Invasive Bladder Carcinoma
Phase 1 / Phase 2Not yet recruitingOhio State University Comprehensive Cancer Center492027-01-152026-10-14
Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for HIVEC in NMIBC.
Hyperthermic intravesical chemotherapy (HIVEC) - Non-muscle Invasive Bladder Cancer (NMIBC)
Not applicableNot yet recruitingEight Medical International BV302027-01-012026-08-14
VA Randomized Trial of Surveillance Intervals After Transurethral Resection of High Grade Bladder Tumors
Low Intensity Surveillance, High Intensity Surveillance - High-Grade Early-Stage Bladder Cancer
Not applicableNot yet recruitingVA Office of Research and Development24822027-01-012026-02-13
Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)
ATO-101™ - Bladder Cancer
Phase 1Not yet recruitingInstitut Cancerologie de l'Ouest242027-01-012026-06-08
DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer
Disitamab Vedotin, Toripalimab, Cetirizine - Bladder Cancer
Phase 1Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University202027-01-012026-11-05
Remote Screening and Navigation to Increase Trial Enrollment, INVITE Trial
Electronic Health Record Review, Patient Navigation, Prescreen - Bladder Carcinoma, Prostate Carcinoma
Not applicableNot yet recruitingFred Hutchinson Cancer Center502027-01-012026-11-06
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
Not applicableNot yet recruitingNatera, Inc.9202027-01-012026-10-27
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma
Phase 1Not yet recruitingAccSalus Biosciences, Inc.402027-01-012026-10-28
The Role of ERBT Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk NMIBC
ERBT and Adjuvant MMC Therapy, ERBT - Bladder Cancer
Not applicableNot yet recruitingChinese University of Hong Kong4402027-01-012026-10-30
Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma
Neoadjuvant Pembrolizumab, Belzutifan, Lenvatinb - Renal Cell Carcinoma
Phase 2Not yet recruitingVall d'Hebron Institute of Oncology1502027-01-012026-11-12

Showing 20 of 4373. Sign in to see all of them.

Narrower conditions

Carcinoma, Renal Cell (1968)  ·  Urinary Bladder Neoplasms (1734)  ·  Kidney Neoplasms (958)  ·  Melanoma (408)  ·  Carcinoma, Non-Small-Cell Lung (398)  ·  Neoplasms (382)  ·  Breast Neoplasms (346)  ·  Carcinoma, Transitional Cell (311)  ·  Prostatic Neoplasms (301)  ·  Ovarian Neoplasms (289)  ·  Non-Muscle Invasive Bladder Neoplasms (286)  ·  Colorectal Neoplasms (282)  ·  Lung Neoplasms (275)  ·  Neoplasm Metastasis (263)  ·  Pancreatic Neoplasms (233)

Broader conditions

Female Urogenital Diseases and Pregnancy Complications (4372)  ·  Female Urogenital Diseases (4370)  ·  Male Urogenital Diseases (4369)  ·  Urogenital Diseases (4368)  ·  Neoplasms by Site (4349)  ·  Urologic Diseases (4338)  ·  Urogenital Neoplasms (4323)  ·  Neoplasms (3991)  ·  Neoplasms by Histologic Type (2880)  ·  Neoplasms, Glandular and Epithelial (2706)  ·  Kidney Diseases (2580)  ·  Carcinoma (2541)  ·  Adenocarcinoma (2022)  ·  Urinary Bladder Diseases (1843)

Interventions

pembrolizumab (231)  ·  Gemcitabine (214)  ·  Nivolumab (191)  ·  Sunitinib (163)  ·  Cisplatin (132)  ·  Sorafenib (100)  ·  Bevacizumab (93)  ·  Magnetic Resonance Spectroscopy (91)  ·  Everolimus (87)  ·  Ipilimumab (84)  ·  Axitinib (79)  ·  cabozantinib (79)  ·  pazopanib (73)  ·  Cyclophosphamide (71)  ·  Specimen Handling (71)

Sponsors

National Cancer Institute (NCI) (231)  ·  M.D. Anderson Cancer Center (100)  ·  Pfizer (92)  ·  Memorial Sloan Kettering Cancer Center (91)  ·  Bristol-Myers Squibb (45)  ·  Merck Sharp & Dohme LLC (42)  ·  Novartis Pharmaceuticals (40)  ·  AstraZeneca (33)  ·  Bayer (33)  ·  Children's Oncology Group (33)  ·  Mansoura University (32)  ·  Hoffmann-La Roche (29)  ·  RenJi Hospital (29)  ·  Eli Lilly and Company (28)  ·  Mayo Clinic (28)

Countries

United States (2260)  ·  China (471)  ·  France (421)  ·  Canada (352)  ·  United Kingdom (335)  ·  Italy (326)  ·  Spain (318)  ·  Germany (245)  ·  Australia (232)  ·  South Korea (220)  ·  Netherlands (210)  ·  Belgium (159)  ·  Japan (140)  ·  Poland (137)  ·  Denmark (128)

Top investigators

Eric Jonasch, MD (13)  ·  Giuseppe Procopio, MD (10)  ·  Sumanta K Pal (9)  ·  Robert J. Motzer, MD (8)

Results publications

PMID 37146227, PMID 31401903, PMID 27238653, PMID 28410911, PMID 25577718, PMID 33526329, PMID 37526095, PMID 32499241, PMID 33058158, PMID 33947608, PMID 34125951, PMID 38045238, PMID 38167321, PMID 39462179, PMID 16389183, PMID 19097774, PMID 22980441, PMID 23964934, PMID 26702763, PMID 26706103, PMID 27279544, PMID 27939400, PMID 29562804, PMID 35304832, PMID 35383907, PMID 36848607, PMID 37933882, PMID 41969229, PMID 11001674, PMID 12118019, PMID 17340590, PMID 17409436, PMID 17452976, PMID 19179301, PMID 19556464, PMID 19687335, PMID 19949018, PMID 20850152, PMID 21403127, PMID 21831711, PMID 21917625, PMID 22002018, PMID 22280855, PMID 22430088, PMID 22512481, PMID 22658127, PMID 22877502, PMID 23228299, PMID 23850254, PMID 23982601

NIH funding

2023 (47), 2017 (28), 2016 (27), 2019 (24), 2018 (22), P30CA033572 (21), U10CA180886 (21), U10CA032102 (18), 2014 (17), P30CA043703 (17), 2015 (16), U10CA031946 (14), U10CA098543 (14), 2025 (13), P30CA015704 (13)